Nextrials' Prism Achieves Compliance Certification
San Ramon, CA-April 6, 2009-Nextrials, Inc., a leader in clinical research software and services, today announced that its award-winning Prism® data capture and clinical trial management platform has achieved certification for compliance with federally recognized Healthcare Information Technology Standards Panel (HITSP) Interoperability Specifications. The company successfully completed compliance testing at the 10th Annual IHE North America Connectathon by demonstrating Prism’s integration of its electronic data capture (EDC) platform used in clinical trials with platforms used by healthcare organizations to maintain electronic health records (EHR) for patients.
Administered by the American National Standards Institute (ANSI), HITSP is a cooperative effort with strategic partners such as the Healthcare Information and Management Systems Society (HIMSS), Integrating the Healthcare Enterprise (IHE), Advanced Technology Institute (ATI) and Booz Allen Hamilton.
Nextrials is again demonstrating Prism’s interoperability at the HIMSS 2009 Interoperability Showcase, part of the 2009 Annual Healthcare Information and Management Systems Society’s Conference & Exhibition, being held April 4-8 in Chicago. Conference attendees can find the showcase in Booth 7750 in the North Hall of McCormick Place.
“Nextrials has dedicated a significant amount of time toward support for ANSI’s work to promote the development and adoption of HITSP standards,” explained James Rogers, CEO and co-founder of Nextrials. “As an early implementer of HITSP interoperability specifications, we recognize the value of integrating electronic health records within clinical trial management systems, which will advance the continuum of patient care and further future clinical research.”
Nextrials’ award-winning Prism melds sophisticated clinical trial management functionality with electronic data capture in a single, integrated package. It is currently used worldwide by biopharmaceutical and medical device R&D teams developing novel treatments and therapeutics.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
